ES2533788T3 - Compuestos inhibidores de PI3K de tipo purina y métodos de uso - Google Patents
Compuestos inhibidores de PI3K de tipo purina y métodos de uso Download PDFInfo
- Publication number
- ES2533788T3 ES2533788T3 ES09755767.2T ES09755767T ES2533788T3 ES 2533788 T3 ES2533788 T3 ES 2533788T3 ES 09755767 T ES09755767 T ES 09755767T ES 2533788 T3 ES2533788 T3 ES 2533788T3
- Authority
- ES
- Spain
- Prior art keywords
- morpholino
- purin
- alkylene
- methyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 9
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- -1 -CH2OH Chemical group 0.000 abstract description 18
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 3
- 125000002947 alkylene group Chemical group 0.000 abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000006736 (C6-C20) aryl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- AOUUDIQPMYTKOI-UHFFFAOYSA-N 1-[2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]acetyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)CCN1C(=O)CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 AOUUDIQPMYTKOI-UHFFFAOYSA-N 0.000 description 1
- WSNVDDJLJHPORH-UHFFFAOYSA-N 1-[3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]propanoyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)CCN1C(=O)CCN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 WSNVDDJLJHPORH-UHFFFAOYSA-N 0.000 description 1
- HKSCZWCKMLMLDU-UHFFFAOYSA-N 1-[3-[[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]methyl]pyrrolidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC1CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 HKSCZWCKMLMLDU-UHFFFAOYSA-N 0.000 description 1
- AGDHHJRWRSOCAF-UHFFFAOYSA-N 1-[4-[[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]methyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 AGDHHJRWRSOCAF-UHFFFAOYSA-N 0.000 description 1
- XHVHZFXNUIYBBO-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-9-methyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2N(C)C(C(C)(C)O)=NC2=C1N1CCOCC1 XHVHZFXNUIYBBO-UHFFFAOYSA-N 0.000 description 1
- KQNBNJOVKJOMDH-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-propylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(CCC)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 KQNBNJOVKJOMDH-UHFFFAOYSA-N 0.000 description 1
- GFRPGDSXDPEGMV-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-(4-methylsulfonylpiperazin-1-yl)ethanone Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 GFRPGDSXDPEGMV-UHFFFAOYSA-N 0.000 description 1
- QQDUFKGDCXYVHR-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-morpholin-4-ylethanone Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CC(=O)N3CCOCC3)C2=N1 QQDUFKGDCXYVHR-UHFFFAOYSA-N 0.000 description 1
- AJVDFTWUNKUSJU-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]acetic acid Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CC(O)=O)C2=N1 AJVDFTWUNKUSJU-UHFFFAOYSA-N 0.000 description 1
- HDTHTJYWODPMJO-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]ethanol Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCO)C2=N1 HDTHTJYWODPMJO-UHFFFAOYSA-N 0.000 description 1
- QJGFOGJKIDPKSZ-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-9-butyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(CCCC)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 QJGFOGJKIDPKSZ-UHFFFAOYSA-N 0.000 description 1
- YWTFMRUDEJHZGF-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-9-methyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(C)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 YWTFMRUDEJHZGF-UHFFFAOYSA-N 0.000 description 1
- LWQWJNNUZUSBMF-UHFFFAOYSA-N 2-[2-(3-hydroxyphenyl)-6-morpholin-4-ylpurin-9-yl]-n-methylacetamide Chemical compound N1=C2N(CC(=O)NC)C=NC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 LWQWJNNUZUSBMF-UHFFFAOYSA-N 0.000 description 1
- XCEDXQNTFRMXPP-UHFFFAOYSA-N 2-[2-(6-aminopyridin-3-yl)-9-methyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(C)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CC=C(N)N=C1 XCEDXQNTFRMXPP-UHFFFAOYSA-N 0.000 description 1
- NMTMVOGZGOVEJE-UHFFFAOYSA-N 2-[4-[[2-(2-amino-4-methylpyrimidin-5-yl)-9-ethyl-6-morpholin-4-ylpurin-8-yl]methyl]piperazin-1-yl]-2-methylpropanamide Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN1CCN(C(C)(C)C(N)=O)CC1 NMTMVOGZGOVEJE-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- GRGVZPAJQCAWAX-UHFFFAOYSA-N 3-(9-benzyl-6-morpholin-4-ylpurin-2-yl)phenol Chemical compound OC1=CC=CC(C=2N=C3N(CC=4C=CC=CC=4)C=NC3=C(N3CCOCC3)N=2)=C1 GRGVZPAJQCAWAX-UHFFFAOYSA-N 0.000 description 1
- NITGMBBDIUJMRW-UHFFFAOYSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-(4-methylsulfonylpiperazin-1-yl)propan-1-one Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)CCN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 NITGMBBDIUJMRW-UHFFFAOYSA-N 0.000 description 1
- NGECFAVNFYGEQO-CQSZACIVSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-[(3r)-3-hydroxypyrrolidin-1-yl]propan-1-one Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCC(=O)N3C[C@H](O)CC3)C2=N1 NGECFAVNFYGEQO-CQSZACIVSA-N 0.000 description 1
- NGECFAVNFYGEQO-AWEZNQCLSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-[(3s)-3-hydroxypyrrolidin-1-yl]propan-1-one Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCC(=O)N3C[C@@H](O)CC3)C2=N1 NGECFAVNFYGEQO-AWEZNQCLSA-N 0.000 description 1
- XHGAULXLKKZIQP-UHFFFAOYSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]propan-1-ol Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCCO)C2=N1 XHGAULXLKKZIQP-UHFFFAOYSA-N 0.000 description 1
- CODFKSZBVMZBRH-UHFFFAOYSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]propanoic acid Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCC(O)=O)C2=N1 CODFKSZBVMZBRH-UHFFFAOYSA-N 0.000 description 1
- ZENYQCKYSXLZEH-UHFFFAOYSA-N 3-[6-morpholin-4-yl-9-(pyridin-4-ylmethyl)purin-2-yl]phenol Chemical compound OC1=CC=CC(C=2N=C3N(CC=4C=CN=CC=4)C=NC3=C(N3CCOCC3)N=2)=C1 ZENYQCKYSXLZEH-UHFFFAOYSA-N 0.000 description 1
- DGAMBEREUILCPV-UHFFFAOYSA-N 3-[9-(2-hydroxyethyl)-6-morpholin-4-ylpurin-2-yl]phenol Chemical compound N1=C2N(CCO)C=NC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 DGAMBEREUILCPV-UHFFFAOYSA-N 0.000 description 1
- NDUUVXXLPJLSJB-UHFFFAOYSA-N 3-[9-(2-methylpropyl)-6-morpholin-4-ylpurin-2-yl]phenol Chemical compound N1=C2N(CC(C)C)C=NC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 NDUUVXXLPJLSJB-UHFFFAOYSA-N 0.000 description 1
- BITPBCRAXMHMRI-UHFFFAOYSA-N 3-[9-[(4-fluorophenyl)methyl]-6-morpholin-4-ylpurin-2-yl]phenol Chemical compound OC1=CC=CC(C=2N=C3N(CC=4C=CC(F)=CC=4)C=NC3=C(N3CCOCC3)N=2)=C1 BITPBCRAXMHMRI-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FXEDTOMEAAGWRT-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-9-(2-methoxyethyl)-8-[(4-methylsulfonylpiperazin-1-yl)methyl]purin-6-yl]morpholine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2N(CCOC)C=1CN1CCN(S(C)(=O)=O)CC1 FXEDTOMEAAGWRT-UHFFFAOYSA-N 0.000 description 1
- AGEYEBVSRFUXAM-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-9-methyl-8-[(4-methylsulfonylpiperazin-1-yl)methyl]purin-6-yl]morpholine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2N(C)C=1CN1CCN(S(C)(=O)=O)CC1 AGEYEBVSRFUXAM-UHFFFAOYSA-N 0.000 description 1
- BSKPTSSXGDEZDB-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-9-methylpurin-6-yl]morpholine Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2N(C)C=NC2=C1N1CCOCC1 BSKPTSSXGDEZDB-UHFFFAOYSA-N 0.000 description 1
- MAXIMYAATWVVQK-UHFFFAOYSA-N 4-[2-(2-methoxypyrimidin-5-yl)-9-methyl-8-[(4-methylsulfonylpiperazin-1-yl)methyl]purin-6-yl]morpholine Chemical compound C1=NC(OC)=NC=C1C1=NC(N2CCOCC2)=C(N=C(CN2CCN(CC2)S(C)(=O)=O)N2C)C2=N1 MAXIMYAATWVVQK-UHFFFAOYSA-N 0.000 description 1
- COJBUQKMQKJJBX-UHFFFAOYSA-N 4-[2-[2-(3-hydroxyphenyl)-6-morpholin-4-ylpurin-9-yl]acetyl]piperazin-2-one Chemical compound OC1=CC=CC(C=2N=C3N(CC(=O)N4CC(=O)NCC4)C=NC3=C(N3CCOCC3)N=2)=C1 COJBUQKMQKJJBX-UHFFFAOYSA-N 0.000 description 1
- MELXZZULKDAPHV-UHFFFAOYSA-N 5-(9-methyl-6-morpholin-4-ylpurin-2-yl)pyridin-2-amine Chemical compound N1=C2N(C)C=NC2=C(N2CCOCC2)N=C1C1=CC=C(N)N=C1 MELXZZULKDAPHV-UHFFFAOYSA-N 0.000 description 1
- OGLQNIWTBCUNNG-UHFFFAOYSA-N 5-(9-methyl-6-morpholin-4-ylpurin-2-yl)pyrimidin-2-amine Chemical compound N1=C2N(C)C=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 OGLQNIWTBCUNNG-UHFFFAOYSA-N 0.000 description 1
- RDSWHFASXQEXJX-UHFFFAOYSA-N 5-[6-morpholin-4-yl-9-(2-morpholin-4-ylethyl)purin-2-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCN3CCOCC3)C2=N1 RDSWHFASXQEXJX-UHFFFAOYSA-N 0.000 description 1
- DTUURQKCKMPNGR-UHFFFAOYSA-N 5-[9-[(3-methoxyphenyl)methyl]-6-morpholin-4-ylpurin-2-yl]pyrimidin-2-amine Chemical compound COC1=CC=CC(CN2C3=NC(=NC(=C3N=C2)N2CCOCC2)C=2C=NC(N)=NC=2)=C1 DTUURQKCKMPNGR-UHFFFAOYSA-N 0.000 description 1
- KAPWFCMMNVOORR-UHFFFAOYSA-N 5-[9-[(4-methylsulfonylphenyl)methyl]-6-morpholin-4-ylpurin-2-yl]pyrimidin-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 KAPWFCMMNVOORR-UHFFFAOYSA-N 0.000 description 1
- TUCAPDBFAOJHOT-UHFFFAOYSA-N 5-[9-ethyl-6-morpholin-4-yl-8-[(4-morpholin-4-ylpiperidin-1-yl)methyl]purin-2-yl]-4-methylpyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN(CC1)CCC1N1CCOCC1 TUCAPDBFAOJHOT-UHFFFAOYSA-N 0.000 description 1
- FPQFBQMNHUKFDS-UHFFFAOYSA-N 5-[9-ethyl-6-morpholin-4-yl-8-[(4-piperidin-1-ylpiperidin-1-yl)methyl]purin-2-yl]-4-methylpyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN(CC1)CCC1N1CCCCC1 FPQFBQMNHUKFDS-UHFFFAOYSA-N 0.000 description 1
- VTAHIFPHJDMNQT-UHFFFAOYSA-N 5-[9-ethyl-6-morpholin-4-yl-8-[(4-piperidin-1-ylpiperidin-1-yl)methyl]purin-2-yl]pyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N(CC)C=1CN(CC1)CCC1N1CCCCC1 VTAHIFPHJDMNQT-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- WHRNQECLXDEWAY-UHFFFAOYSA-N n-[1-[[2-(2-amino-4-methylpyrimidin-5-yl)-9-ethyl-6-morpholin-4-ylpurin-8-yl]methyl]piperidin-4-yl]-n-methylmethanesulfonamide Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN1CCC(N(C)S(C)(=O)=O)CC1 WHRNQECLXDEWAY-UHFFFAOYSA-N 0.000 description 1
- KSQHFCOCMGKFHC-UHFFFAOYSA-N n-[1-[[2-(2-aminopyrimidin-5-yl)-9-ethyl-6-morpholin-4-ylpurin-8-yl]methyl]piperidin-4-yl]-n-methylmethanesulfonamide Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N(CC)C=1CN1CCC(N(C)S(C)(=O)=O)CC1 KSQHFCOCMGKFHC-UHFFFAOYSA-N 0.000 description 1
- BMEOUALTYJSZAF-UHFFFAOYSA-N n-[4-[9-methyl-8-[(4-methylsulfonylpiperazin-1-yl)methyl]-6-morpholin-4-ylpurin-2-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(N2CCOCC2)=C(N=C(CN2CCN(CC2)S(C)(=O)=O)N2C)C2=N1 BMEOUALTYJSZAF-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5755908P | 2008-05-30 | 2008-05-30 | |
| US57559 | 2008-05-30 | ||
| PCT/US2009/045603 WO2009146406A1 (en) | 2008-05-30 | 2009-05-29 | Purine pi3k inhibitor compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2533788T3 true ES2533788T3 (es) | 2015-04-14 |
Family
ID=41017038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09755767.2T Active ES2533788T3 (es) | 2008-05-30 | 2009-05-29 | Compuestos inhibidores de PI3K de tipo purina y métodos de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8158624B2 (OSRAM) |
| EP (1) | EP2279188B1 (OSRAM) |
| JP (1) | JP2011521968A (OSRAM) |
| KR (1) | KR20110042153A (OSRAM) |
| CN (1) | CN102105474B (OSRAM) |
| AU (1) | AU2009251291B2 (OSRAM) |
| BR (1) | BRPI0909614A2 (OSRAM) |
| CA (1) | CA2721851A1 (OSRAM) |
| ES (1) | ES2533788T3 (OSRAM) |
| IL (1) | IL208838A0 (OSRAM) |
| MX (1) | MX2010012583A (OSRAM) |
| RU (1) | RU2509081C2 (OSRAM) |
| WO (1) | WO2009146406A1 (OSRAM) |
| ZA (1) | ZA201007524B (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889015B (zh) | 2007-10-05 | 2014-06-04 | 维拉斯通股份有限公司 | 嘧啶取代的嘌呤衍生物 |
| CA2701292C (en) * | 2007-10-25 | 2015-03-24 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| CA2703138A1 (en) * | 2007-10-26 | 2009-04-30 | F. Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
| GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| MX358640B (es) | 2008-01-04 | 2018-08-29 | Intellikine Llc | Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| MX2011010332A (es) | 2009-04-03 | 2011-11-29 | S Bio Pte Ltd | Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s). |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| EP2451811A1 (en) * | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| CA2761445A1 (en) * | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| MX2012005463A (es) * | 2009-11-12 | 2012-09-12 | Hoffmann La Roche | Compuestos de purina n/9 sustituida, composiciones y metodos de uso. |
| BR112012011147A2 (pt) * | 2009-11-12 | 2021-09-08 | F.Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto. |
| EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CN103003279B (zh) | 2010-07-14 | 2015-09-23 | 弗·哈夫曼-拉罗切有限公司 | 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法 |
| ES2612503T3 (es) * | 2010-09-14 | 2017-05-17 | Exelixis, Inc. | Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| EP3053925A1 (en) * | 2010-12-16 | 2016-08-10 | F. Hoffmann-La Roche AG | Tricyclic pi3k inhibitor compounds and methods of use |
| TWI546305B (zh) | 2011-01-10 | 2016-08-21 | 英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| WO2012156379A1 (en) | 2011-05-13 | 2012-11-22 | Universität Zürich | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| JP2014529298A (ja) * | 2011-07-28 | 2014-11-06 | ジェネンテック， インコーポレイテッド | Ｐｉｋ３ｃａｈ１０４７ｒノックイン非ヒト動物乳癌モデル |
| CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| US20150011569A1 (en) * | 2011-12-15 | 2015-01-08 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20160027218A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| CN105102000B (zh) | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
| CN103936742B (zh) * | 2013-01-17 | 2017-05-03 | 程鹏 | 含嘌呤基的新型pi3k抑制剂及其制备方法和应用 |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| PE20151977A1 (es) * | 2013-05-02 | 2016-01-07 | Hoffmann La Roche | Nuevos derivados de purina |
| WO2014185367A1 (ja) * | 2013-05-13 | 2014-11-20 | 第一三共株式会社 | モルホリノプリン誘導体の製造方法 |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN104557872B (zh) * | 2013-10-16 | 2017-05-24 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
| CN103804380B (zh) * | 2014-01-24 | 2016-05-18 | 温州医科大学 | 以IKK-β为靶点的2-氨基-8-取代鸟嘌呤衍生物、应用及其制备方法 |
| EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015188369A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10172942B2 (en) * | 2014-12-17 | 2019-01-08 | Pfizer Inc. | Formulations of a PI3K/mTor-inhibitor for intravenous administration |
| TWI689508B (zh) | 2015-03-30 | 2020-04-01 | 日商第一三共股份有限公司 | 可作爲ｐｉ３ｋ抑制劑之吡唑衍生物及其用途 |
| PL236355B1 (pl) * | 2015-04-02 | 2021-01-11 | Celon Pharma Spolka Akcyjna | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
| KR102015826B1 (ko) * | 2015-04-21 | 2019-08-29 | 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 | 퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도 |
| WO2016205334A1 (en) | 2015-06-16 | 2016-12-22 | Vascular Strategies Llc | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| EP3521290A4 (en) * | 2016-09-29 | 2020-04-22 | Daiichi Sankyo Company, Limited | CRYSTALS OF [2- (1-METHYL-1H-PYRAZOL-4-YL) -6- (MORPHOLIN-4-YL) -9H-PURIN-8-YL] [4- (MORPHOLIN-4-YL) PIPERIDIN-1 -YL] METHANONE AND PHARMACEUTICAL SAFE SALT THEREOF |
| KR102399639B1 (ko) | 2016-12-02 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
| AU2019345706B2 (en) * | 2018-09-27 | 2024-02-22 | Shanghai Yingli Pharmaceutical Co., Ltd | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof |
| AR120173A1 (es) * | 2019-10-09 | 2022-02-02 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| CN111875606B (zh) * | 2020-07-20 | 2023-04-07 | 武汉工程大学 | 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN116425751B (zh) * | 2022-12-19 | 2024-01-23 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的多环类化合物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016378A (en) | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| DE3406533A1 (de) | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
| US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| JP2003146987A (ja) * | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| JP2005504789A (ja) | 2001-09-13 | 2005-02-17 | シンタ ファーマスーティカルズ コーポレイション | 癌治療のための２−アロイルイミダゾール化合物 |
| US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
| AU2002342051B2 (en) | 2001-10-12 | 2009-06-11 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
| AU2002357295A1 (en) * | 2001-12-18 | 2003-06-30 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| JP2006503826A (ja) * | 2002-09-06 | 2006-02-02 | スミスクライン・ビーチャム・コーポレイション | ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物 |
| US7122665B2 (en) | 2002-10-15 | 2006-10-17 | Synta Pharmaceuticals Corp. | Heterocyclic compounds |
| TW200510394A (en) | 2003-05-29 | 2005-03-16 | Synta Pharmaceuticals Corp | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| MX2008013583A (es) * | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
| AR063142A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
| US20080233127A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| JP5703432B2 (ja) * | 2007-03-28 | 2015-04-22 | ノイロサーチ アクティーゼルスカブ | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| EP2142545A1 (en) * | 2007-03-28 | 2010-01-13 | NeuroSearch A/S | Purinyl derivatives and their use as potassium channel modulators |
| CA2703138A1 (en) * | 2007-10-26 | 2009-04-30 | F. Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| MX2011010332A (es) * | 2009-04-03 | 2011-11-29 | S Bio Pte Ltd | Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s). |
| EP2451811A1 (en) * | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| CA2761445A1 (en) * | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| MX2012005463A (es) * | 2009-11-12 | 2012-09-12 | Hoffmann La Roche | Compuestos de purina n/9 sustituida, composiciones y metodos de uso. |
| CN103003279B (zh) * | 2010-07-14 | 2015-09-23 | 弗·哈夫曼-拉罗切有限公司 | 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法 |
-
2009
- 2009-05-29 US US12/474,613 patent/US8158624B2/en active Active
- 2009-05-29 AU AU2009251291A patent/AU2009251291B2/en not_active Ceased
- 2009-05-29 CA CA2721851A patent/CA2721851A1/en not_active Abandoned
- 2009-05-29 WO PCT/US2009/045603 patent/WO2009146406A1/en not_active Ceased
- 2009-05-29 EP EP09755767.2A patent/EP2279188B1/en active Active
- 2009-05-29 MX MX2010012583A patent/MX2010012583A/es active IP Right Grant
- 2009-05-29 KR KR1020107026673A patent/KR20110042153A/ko not_active Ceased
- 2009-05-29 CN CN200980129148.2A patent/CN102105474B/zh active Active
- 2009-05-29 JP JP2011511842A patent/JP2011521968A/ja active Pending
- 2009-05-29 ES ES09755767.2T patent/ES2533788T3/es active Active
- 2009-05-29 RU RU2010154428/04A patent/RU2509081C2/ru not_active IP Right Cessation
- 2009-05-29 BR BRPI0909614A patent/BRPI0909614A2/pt not_active Application Discontinuation
-
2010
- 2010-10-20 IL IL208838A patent/IL208838A0/en unknown
- 2010-10-21 ZA ZA2010/07524A patent/ZA201007524B/en unknown
-
2012
- 2012-02-09 US US13/369,941 patent/US8445487B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201007524B (en) | 2012-01-25 |
| RU2509081C2 (ru) | 2014-03-10 |
| IL208838A0 (en) | 2011-01-31 |
| RU2010154428A (ru) | 2012-07-10 |
| AU2009251291B2 (en) | 2013-05-02 |
| US8158624B2 (en) | 2012-04-17 |
| KR20110042153A (ko) | 2011-04-25 |
| WO2009146406A1 (en) | 2009-12-03 |
| BRPI0909614A2 (pt) | 2015-09-22 |
| AU2009251291A1 (en) | 2009-12-03 |
| EP2279188B1 (en) | 2015-01-28 |
| JP2011521968A (ja) | 2011-07-28 |
| US8445487B2 (en) | 2013-05-21 |
| CN102105474B (zh) | 2014-01-08 |
| EP2279188A1 (en) | 2011-02-02 |
| CA2721851A1 (en) | 2009-12-03 |
| US20090318411A1 (en) | 2009-12-24 |
| CN102105474A (zh) | 2011-06-22 |
| US20120135988A1 (en) | 2012-05-31 |
| MX2010012583A (es) | 2011-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2533788T3 (es) | Compuestos inhibidores de PI3K de tipo purina y métodos de uso | |
| KR101873672B1 (ko) | Ｉｄｏ１ 억제제로서 사용하기 위한 피롤리딘-２,５-디온 유도체, 제약 조성물 및 방법 | |
| ES2644724T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| EP3056207B1 (en) | Therapeutic compounds and related methods of use | |
| AU2012327210B2 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| ES2882797T3 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| JP2017505346A (ja) | 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法 | |
| ES2400257T3 (es) | Aminopurinas sustituidas con haloarilo, sus composiciones y métodos de tratamiento asociados | |
| JP6896852B2 (ja) | Ｆｇｆｒ阻害剤として使用される複素環式化合物 | |
| RU2008145701A (ru) | Производные пурина для применения в качестве агонистов аденозинового рецептора a2a | |
| RU2011100786A (ru) | Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ | |
| CA2681250A1 (en) | Chemical compounds | |
| ES2875737T3 (es) | Derivados de 2-fenil-3H-imidazo[4,5-b]piridina útiles como inhibidores de la actividad tirosina quinasa de ROR1 de mamíferos | |
| AR066659A1 (es) | Derivados de espiroindolinona | |
| JP2011507851A (ja) | Ｒｈｏキナーゼインヒビターとしてのベンゾイミダゾールおよびアナログ | |
| ES2558608T3 (es) | Derivados hetero-bicíclicos como inhibidores del VHC | |
| PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
| AR084401A1 (es) | COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS | |
| KR20100051814A (ko) | Ｇｐｒ１１９ ｇ 단백질-커플링된 수용체의 조절 방법 및 선택된 화합물 | |
| KR20080107466A (ko) | 대사 장애 치료용 8-헤테로아릴퓨린 ｍｎｋ2 억제제 | |
| PE20081159A1 (es) | Inhibidores de las quinasas y metodos para su utilizacion | |
| BR112014015720B1 (pt) | Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| ES2820553T3 (es) | Compuesto y composición farmacéutica para trastorno neuropsicológico o tumor maligno | |
| AR085637A1 (es) | Derivados de pirido[2,3-b]pirazina |